On December 12, 2019, the Intellectual Property Tribunal of the Supreme Court of China had a public decision on the patent infringement case filed by Societe d' Elastographie Impulsionnelle pour les Systemes de Mesure de l' Elasticite (SEISME), a subsidiary of Echosens, against Wuxi Hisky Medical Technologies Co., Ltd. (hereinafter referred to as “HISKY”).
According to the court decisions, HISKY's technical solution of the sued products is different from Echosens' patent involved in the case and does not constitute patent infringement. The Supreme Court of China reversed the original judgement made by the lower court, Beijing’s Intellectual Property Court, on February 1, 2019. All claims of SEIME were dismissed, and SEISME was requested to bear the litigation costs.
Regarding the final judgement of this case, HISKY would like to state as follows.
1. The intellectual property rights of HISKY’s non-invasive liver fibrosis detection system are recognized by the Supreme Court of China. This case is the most important case among many IP cases initiated by Echosens against HISKY over the years. The final judgement of this case means that the battle over the intellectual property rights in the field of liver fibrosis diagnosis has ended. The core technologies of FT series products and its trademark are legally protected.
2. HISKY has always valued the intellectual properties. HISKY has independent intellectual property rights and core technologies in the field of non-invasive liver fibrosis detection. It is also one of the global companies with the largest number of intellectual property rights in this field. So far, HISKY has applied for over 300 patents and more than 180 trademarks worldwide, covering over 20 countries. The patent of "Ultrasonic non-destructive detection method and device of viscoelastic medium" won the 20th China Patent Excellence Award, which is the top national patent award in China.
3. HISKY has been focusing on the research and development of the technologies of liver fibrosis detection, and has carried out extensive cooperation with a number of well-known medical and research institutions. It has received CE and US FDA 510(k) clearance for the FT series products. HISKY has installed FT series products in over 1,000 hospitals, used on an estimated millions of patients across the global market, which has produced great social benefits.
HISKY is committed to provide quality products and services to physicians and patients, and will continue to invest in innovation and research. From the beginning, HISKY filled the gap in the field of Transient Elastography in China and introduced image-guided non-invasive liver fibrosis detection system, breaking the technology and market exclusivity of European company, to today, HIKSY developed several globally unique technologies and launched the new generation of iLivTouch series products, which can provide more convenient, accurate and comprehensive detection of liver disease. In future, HISKY will always strive to contribute to the mission of prevention and treatment of liver disease.
HISKY thanks its global customers and distribution partners for their continued support.